| Literature DB >> 33004028 |
Noellie Gay1, Nathalie Lugagne2, Guillaume Miltgen3,4, Olivier Belmonte3, Eric Cardinale5,6.
Abstract
BACKGROUND: In 2015, antimicrobial resistance was identified as a public health priority for the South-Western Indian Ocean (SWIO) (i.e. Comoros, Madagascar, Mauritius, Mayotte (France), Reunion Island (France), and Seychelles). However, in 2020, colonization rates of antimicrobial-resistant bacteria (ARB) in human populations on most islands in SWIO were still not known and neither hospital nor community colonization rates had been estimated. The aim of this study was to estimate the prevalence of colonization of six ARB groups in hospitalized patients residing in the SWIO territories. The six groups comprise extended-spectrum betalactamase producing Enterobacteriaceae (ESBL-E), carbapenem-resistant Enterobacteriaceae (CRE), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), and both ceftazidime and/or imipenem-resistant Acinetobacter spp. (ACB), and ceftazidime and/or imipenem-resistant Pseudomonas spp. (PSA)).Entities:
Keywords: Colonization; Epidemiology; Hospital; Indian Ocean; Multidrug resistance; Screening
Mesh:
Substances:
Year: 2020 PMID: 33004028 PMCID: PMC7528459 DOI: 10.1186/s12889-020-09591-8
Source DB: PubMed Journal: BMC Public Health ISSN: 1471-2458 Impact factor: 3.295
Fig. 1ARB colonization rates according to the patient’s territory of residence in the South-Western Indian Ocean. * An ARB positive patient could be a carrier of more than one ARB group; ESBL-E: extended-spectrum betalactamase producing Enterobacteriaceae; MRSA: methicillin-resistant Staphylococcus aureus; CRE: carbapenem-resistant Enterobacteriaceae; ACB: ceftazidime and/or imipenem-resistant Acinetobacter spp.; VRE: vancomycin-resistant enterococci.; PSA: ceftazidime and/or imipenem-resistant Pseudomonas spp.
Comparison of ARB colonization rates according to the patient’s territory of residence (2015–2017) using Reunion Island (France) as reference
| Patients (n) | ARB positive patients | ESBL-E | MRSA | CRE | |||||
|---|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | Prevalence (95% CI) | OR (95% CI) | Prevalence (95% CI) | OR (95% CI) | Prevalence (95% CI) | OR (95% CI) | Prevalence (95% CI) | ||
| Seychelles | 13 | 61.5% [35.5–82.3%] | 61.5% [35.5–82.3%] | 15.4% [4.3–42.2%] | _ | _ | |||
| Madagascar | 322 | 41.3% [36.1–46.8%] | 40.1% [34.9–45.5%] | 2.3 [0.7–6.6] | 1.2% [0.5–3.2%] | 2.7 [0.8–8.2] | 1.2% [0.5–3.2%] | ||
| Comoros | 30 | 33.3% [19.2–51.2%] | 33.3% [19.2–51.2%] | _ | _ | _ | _ | ||
| Mayotte | 1475 | 26.4% [24.3–28.8%] | 24.7% [22.5–26.9%] | 2.0% [1.4–2.8%] | 2.1 [0.9–4.8] | 0.9% [0.6–1.6%] | |||
| Mauritius | 111 | 1.5 [1.0–2.4] | 26.1% [18.9–35.0%] | 1.1 [0.7–1.8] | 19.8% [13.5–28.2%] | _ | _ | 8.1% [4.3–14.7%] | |
| Reunion | 2184 | 1 (ref) | 18.7% [17.1–20.4%] | 1 (ref) | 17.9% [16.3–19.5%] | 1 (ref) | 0.5% [0.3–1.0%] | 1 (ref) | 0.5% [0.2–0.8%] |
ARB Antimicrobial-resistant bacteria, ESBL-E Extended-spectrum betalactamase producing Enterobacteriaceae, MRSA Methicillin-resistant Staphylococcus aureus, CRE Carbapenem-resistant Enterobacteriaceae, OR Odds ratio, CI Confidence interval, ref. reference for odds ratio estimation; ** ≤ 0.001; * < 0.05; ACB, PSA, and VRE are not presented here as odds ratio were not significant